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OBJECTIVES: To assess the prevalence and adequacy of warfarin use in patients with 
atrial ﬁbrillation (AF) according to stroke risk, as assessed by CHADS2 scores, in a 
nationally representative patient sample. METHODS: The data source was GE’s 
Medical Quality Improvement Consortium (MQIC) database (February 2009) con-
taining electronic medical records (EMRs) data on 11 million patients in the U.S. 
Eligible patients were those with a diagnosis of AF, qage 40 years at AF diagnosis, 
and with no use of warfarin or antiplatelet agents at anytime prior to AF diagnosis. 
Ineligible patients were those who might have other reasons, such as cancer or ortho-
pedic surgery, to be hypercoagulable (i.e. other justiﬁcations for different anticoagu-
lant use or INR ranges), or those already on antiplatelet agents or warfarin prior to 
AF diagnosis. CHADS2 stroke risk scores were assigned on the basis of conditions 
prior to or coincident with the AF diagnosis (congestive heart failure, hypertension, 
diabetes mellitus, stroke/TIA). The last INR on record was captured for all eligible 
patients. RESULTS: From 11,196,881 total patients, 58,848 patients with AF met all 
selection criteria. Patients at high risk of stroke (CHADS2 q 2) comprised 99%   
(58,214) of the total patients. Among the high risk patients, 24,953 (43%) were on 
warfarin, 8,541 (15%) antiplatelet agents, and 24,720 (42%) neither. Of the 24,953 
patients on warfarin, the last INR on record was in the suboptimal range (2) in 
13,198 (53%), above optimal range (3) in 2,969 (12%), and in optimal range (2–3) 
in 8786 (35%). CONCLUSIONS: Analysis of a large, nationally representative EMR 
database suggests that the majority of AF patients at increased risk of stroke are 
receiving suboptimal anticoagulation.
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HEART FAILURE IN OLDER PEOPLE: A STUDY OF FACTORS THAT 
LEAD TO HOSPITALISATION
Brown SH, Abdelhaﬁz AH
Rotherham General Hospital, Rotherham, UK
OBJECTIVES: Heart failure is a frequent cause of hospitalisation among older 
patients. This study examines the principal factors leading to acute decompensation 
of heart failure leading to hospital admission and considers whether these factors 
are avoidable. METHODS: We conducted a retrospective casenote study of all 
patients admitted to the department of Geriatric Medicine over a 2 year period 
who had a principal discharge diagnosis of heart failure (ICD codes 428.0, 428.1, 
428.9). Demographic and clinical data on medical history, clinical examination, 
radiographic ﬁndings, echocardiography, blood tests and medications was collected. 
Each case was evaluated to determine the factor that contributed most to heart 
failure decompensation. Main factors leading to hospitalisation included: volume 
overload if patient had all signs of hypervolaemia (pedal oedema, elevated jugular 
venous pressure, pulmonary crepitations and dilutional hyponatraemia), tachyarrhyth-
mia if heart rate was 150 beats per minute, or uncontrolled hypertension if systolic 
blood pressure 180mmHg. RESULTS: The study sample included 145 patients. 
Mean (SD) age was 82(5) years and 74 (51%) were women. All patients were taking 
diuretics and 75 (51.5%) were taking angiotensin converting enzyme inhibitors. 
Twenty two (15.2%) were taking non steroidal anti-inﬂammatory drugs (NSAIDs). 
Risk factors for admission were identiﬁed in this rank order: volume overload 52 
(35.9%) patients, chest infection 26 (17.9%) patients, combination of volume over-
load and chest infection 19 (13.1%) patients, myocardial infarction 17 (11.7%) 
patients, tachyarrhythmia (mainly atrial ﬁbrillation) 9 (6.2%) patients, uncontrolled 
hypertension 10 (6.9%) and pulmonary embolus 1 (0.7%). In 11 (7.6%) patients 
no precipitating factor could be determined. Of the 52 patients with volume overload 
12 (23.1%) were receiving NSAIDs on admission. CONCLUSIONS: Our ﬁndings 
show that factors leading to hospitalisation for heart failure may be amenable 
to intervention, particularly volume overload. Patient education regarding diet 
and medication, especially NSAIDs, and regular monitoring of blood pressure should 
be considered.
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DETERMINING A MODEL-DERIVED RELATIVE STROKE RISK 
THRESHOLD TO JUSTIFY CAROTID STENTING IN SURGICAL  
HIGH-RISK PATIENTS
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OBJECTIVES: To estimate the threshold of relative stroke risk needed that makes 
medical management inferior to protected carotid stenting in asymptomatic patients 
with carotid artery stenosis and substantial cardiovascular comorbidities. METHODS: 
A validated and published Monte Carlo microsimulation model created a stroke-free, 
two-year survival curve in monthly increments for a hypothetical medically managed 
arm of a recent single-arm carotid revascularization trial in patients at high surgical 
risk due to their cardiovascular comorbidities. Using a log rank test the actual two-year 
survival curve from the ACCULINK for Revascularization of Carotids in High-Risk 
patients (ARCHeR) trial data was compared to the medically-managed curve gener-
ated by the model. The model stroke risk equations were generated from the general 
population and calibrated for patients with asymptomatic carotid artery stenosis but 
otherwise healthy. Relative stroke risks between these patients and the surgical high-
risk patients were estimated from the stroke rates of the intervention arm of a trial 
with more restrictive inclusion criteria (ACAS) and the strokes rates of ARCHeR. 
RESULTS: Using the best estimate of relative risk (2.02) the one- and two-year stroke 
rates for medical management were 0.901 and 0.851, respectively. This compares to 
0.934 and 0.879 from the ARCHeR trial using protected carotid stenting. The Chi-
square statistic from the log rank test of two-year survival curves was 2.26; p  0.13 
that medical management produces different results from carotid stenting. As long as 
the relative risk is greater than 2.25 the p value is 0.05. CONCLUSIONS: Recent 
carotid stenosis trials lack medically managed populations, but a model can estimate 
stroke-free survival and mortality data for these patients if the relative risk compared 
to a known population can be estimated. Since the ARCHeR trial found no ipsilateral 
strokes in its third year, this two-year analysis may overestimate the relative risk 
needed to justify carotid stenting.
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PERFLUTREN PROTEIN-TYPE A MICROSPHERES INJECTABLE 
SUSPENSION, USP DOES NOT INCREASE MORTALITY IN CRITICALLY 
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MATCHED CASE-CONTROL STUDY
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OBJECTIVES: Due to serious cardiopulmonary reactions reported immediately 
following administration of perﬂutren containing contrast agents , the United States 
Food and Drug Administration (FDA) required a Black Box Safety warning for 
this class of agents including Perﬂutren Protein-Type A Microspheres Injectable 
Suspension , USP. The FDA has requested a database analysis to compare in-hospital 
mortality in critically ill patients undergoing echocardiography with and without 
this contrast agent. This study provides results of the retrospective analysis. 
METHODS: This study utilized the largest hospital service-level database in the US. 
All adult patients undergoing inpatient echocardiography between January 2003 
and October 2005 were identiﬁed (n  2 ,588 ,722 of which 22 ,499 received 
Perﬂutren Protein-Type A Microspheres Injectable Suspension, USP). From the 22 ,499 
contrast echocardiography patients, 2,900 had diagnoses meeting criteria for critical 
illness (heart failure, acute myocardial infarction, arrhythmia, respiratory failure, 
pulmonary embolism, emphysema , and pulmonary hypertension). To control for 
the differences between the contrast and non-contrast patients we used propensity 
score matching. Variables used in the construction of the propensity score included 
comorbidities , demographic factors , hospital-speciﬁc factors , level of care, and 
mechanical ventilation status. Patients receiving contrast echocardiography were 
matched to 4 controls who received non-contrast echocardiography. Conditional 
logistic regression was used to estimate mortality effects. RESULTS: There were 167 
deaths in the study among critically ill patients, 38/2900 from the contrast group and 
129/11600 from the control group. The contrast agent was not associated with an 
increase in same-day mortality (odds ratio  1.18 (95% C.I. 0.82, 1.71); P  0.37)). 
Prior to matching, contrast patients showed greater morbidity then non-contrast 
patients (Deyo-Charlson Comorbidity Score 2.45 vs. 2.25, P  0.0001). After propen-
sity-score matching these differences were signiﬁcantly reduced, showing that both 
groups were well-balanced. CONCLUSIONS: There is no increase in mortality in 
critically ill patients undergoing echocardiography with the contrast agent compared 
to case-matched controls.
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DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) AND  
ALL-CAUSE MORTALITY
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OBJECTIVES: Health beneﬁts of low-density lipoprotein cholesterol (LDL-C) at rec-
ommended levels are well known; beneﬁts of HDL-C at recommended levels are less 
well documented. This study assesses and replicates the quantiﬁcation of the relation-
ship between HDL-C and all-cause mortality while aligning relative importance to 
LDL-C. METHODS: A comprehensive analyses of available epidemiological studies 
including HDL-C and all-cause mortality as an endpoint were included in a meta-
regression. That meta-regression was independently validated with a longitudinal 
analysis of an Australian epidemiological database (General Practitioner Research 
Network) 1999–2008. While statistical association is important, demonstration that 
modiﬁcations via intervention to the clinical measure (HDL-C) effect change in the 
endpoint is more important. RESULTS: Twenty-two epidemiological studies in 
153,798 patients met the criteria. In a survival analysis for time to death, higher 
HDL-C is signiﬁcantly associated with longer duration to death (P  0.043); 
0.33 mmol/L higher HDL and 1.33 lower total/HDL cholesterol were each associated 
with about a third lower vascular mortality. Twenty-ﬁve placebo-controlled interven-
tion trials yielded a regression that explained 83% of the variation in percent changes 
in cardiovascular events with parameter estimates associated with percent changes in 
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HDL-C and LDL-C of 1.51 (P  0.02) and 1.02 (P  0.02). Alternatively, a 1% 
increase in HDL-C equates to a 1.5% change in cardiovascular events while a 1% 
reduction in LDL-C equates to a 1% reduction in those events. HDL-C is statistically 
signiﬁcantly inversely related to mortality. Higher HDL-C is associated with a decrease 
in the likelihood of death (1.73; P  0.04) while repeated measures that are higher 
further decrease that probability (0.01: P  0.02). Lower LDL-C decreases the 
probability of death. CONCLUSIONS: The relationship between HDL-C and all-
cause mortality was quantiﬁed, replicated and validated and shown to be of greater 
prognostic value than LDL-C.
CARDIOVASCULAR DISORDERS – Cost Studies
PCV48
A GERMAN HOSPITAL BUDGET IMPACT MODEL COMPARING 
ANTICOAGULATION STRATEGIES IN PERCUTANEOUS  
CORONARY INTERVENTION
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OBJECTIVES: Approximately 230,000 percutaneous coronary interventions (PCIs) 
were performed in the Germany in 2005. PCI complications often increase resource 
utilization. New antithrombotic therapies have the potential to improve outcomes and          
decrease costs. The ACUITY and HORIZONS-AMI studies demonstrated improved 
clinical event rates (mortality and bleeding) using bivalirudin compared to a heparin-
plus-GPI regimen. This analysis evaluated the economic impact of this improvement 
in the German hospital setting. METHODS: A budget-impact model was developed 
to evaluate the impact of bivalirudin in unstable angina (UA)/non-ST-elevated myo-
cardial infarction (NSTEMI) patients undergoing PCI in a German hospital. Clinical 
data for the model were derived from the ACUITY trial and included 30-day event 
rates for major complications (major and minor bleeding as deﬁned by trial protocol, 
Q-wave myocardial infarction, repeat PCI and coronary artery bypass graft [CABG]). 
Economic data were derived from the medical literature, including clinical outcomes 
as well as ward costs (both regular and ICU/CCU) and pharmaceutical costs. Addi-
tional analysis using resource use data from the ADONIS registry was performed. A 
subgroup of high risk patients (per ESC deﬁnition) was also examined in the model. 
RESULTS: For UA/NSTEMI patients, overall average per procedure cost was a5347 
with heparin plus GPI and a4822 with bivalirudin. In 100 PCI patients, bivalirudin 
use would result in 3 fewer major bleeding events (3.1%) and 11 fewer minor bleeding 
events (10.7%). Total hospital costs comparing 100% heparin-based strategy to 100% 
bivalirudin-based strategy were a341,473 and a289,025, respectively, resulting in a 
cost-savings with bivalirudin of a52,448 (15%). For high risk UA/NSTEMI patients 
the cost-savings over 100 procedures are a56,233 (16%). CONCLUSIONS: A bivali-
rudin-based strategy for anticoagulant use in UA/NSTEMI patients undergoing PCI is 
associated with favorable clinical and economic outcomes when compared with 
heparin plus GPI in a German hospital setting.
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FINANCIAL IMPACT OF A NOVEL PREECLAMPSIA DIAGNOSTIC TEST 
VS. STANDARD CARE: A DECISION-ANALYTIC MODELING ANALYSIS 
FROM A GERMAN HEALTH CARE PAYER PERSPECTIVE
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OBJECTIVES: Preeclampsia, a leading cause of maternal and perinatal morbidity and 
mortality, is only detected after the onset of clinical symptoms. Earlier diagnosis may 
be possible with a new serum test using soluble fms-like tyrosine kinase-1 (sFlt-1) and 
placental growth factor (PlGF) biomarkers. Clinical and economic beneﬁts may result 
from appropriate detection and management of subclinical cases, and from averting 
costs associated with incorrect diagnoses. We evaluated the ﬁnancial impact of the 
novel test versus standard care from a German health care payer perspective. 
METHODS: We developed a decision-analytic model of the clinical and economic 
impact resulting from improved sensitivity and speciﬁcity of the new test over current 
diagnostic practice. Acute management and follow-up costs were associated with true 
positive, true negative, false positive, and false negative diagnoses. The base-case 
analysis assumed that, of all pregnant women, 10% present with risk factors while 
90% do not. The CHF 52 (a-equivalent) test was assumed to be administered after 
20 weeks of gestation. True positive and false negative patients were assumed to enter 
one of four health states: mild preeclampsia; severe preeclampsia; eclampsia; or death. 
Data pertaining to treatment practices, health care resource utilization, incidence, 
costs, and funding for detection and management of preeclampsia in Germany were 
obtained through interviews with clinicians, laboratory managers, and health care 
payers in Germany. Additional data were obtained from published literature and 
public databases. RESULTS: Model results suggest that when used for screening, the 
novel test would reduce false negative diagnoses of preeclampsia by 67% and false 
positives by 71%. Costs per patient are estimated to be a941 with the novel test and 
a1578 with standard practice, saving an estimated a637 per patient given the novel 
test. CONCLUSIONS: This test has the potential to improve detection and manage-
ment of preeclampsia translating into substantial cost savings for German health care 
payers.
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OBJECTIVES: Approximately 5900 PPCIs were performed in the UK in 2007. This 
number is expected to double in the next 5 years post the 2008 NIAP report. New 
antithrombotic therapies have the potential to improve clinical outcomes and decrease 
costs. The HORIZONS-AMI study of bivalirudin demonstrated reduced clinical event 
rates (mortality and bleeding) compared to a heparin and GPI (HEPGPI) regimen. 
The potential economic value of implementing bivalirudin in the PPCI setting is evalu-
ated in this analysis from the UK hospital perspective. METHODS: A budget impact 
model was developed to compare treatment of STEMI patients undergoing PPCI with 
either bivalirudin or HEPGPI. Clinical data for the model was derived from the 
HORIZONS trial, and included 30-day event rates for major complications (major 
and minor bleeding as deﬁned by trial protocol, Q-wave myocardial infarction [MI], 
and repeat PCI and coronary artery bypass graft [CABG] procedures). UK cost and 
clinical practice data were derived from published sources. RESULTS: Overall average 
procedure cost per bivalirudin-treated patient (incorporating 7.2% provisional GPI 
use as per HORIZONS) was £4284, compared to £5015 per HEPGPI-treated patient. 
In extrapolating these beneﬁts to a typical NHS hospital of 200 PPCI patients per 
year, 7 major bleeding events (3.4%), 13 minor bleeding events (6.6%), and 2 deaths 
(1%) in patients would be averted if treated with bivalirudin. The total hospital budget 
impact of treating 200 PPCI patients using a HEPGPI based strategy is £1,002,913. 
Introducing a bivalirudin-based strategy could save £146,129 (15%) per year. CON-
CLUSIONS: Using a bivalirudin-based strategy in STEMI patients undergoing PPCI 
is associated with favorable clinical and economic outcomes when compared with 
HEPGP in a UK hospital setting.
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THE POTENTIAL ECONOMIC IMPACT OF RECONFIGURING TIA CARE 
IN ITALY
Jackson D1, Moshinsky J2, Begg A2
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OBJECTIVES: Due to a lack of awareness of Transient Ischaemic Attack (TIA) 
symptoms, many patients may not immediately seek medical help, creating a delay in 
access to treatment. The UK EXPRESS study by Rothwell et al. (Lancet 2007;370:1432–
42) demonstrated that greater focus on effectively managing TIA could have a signiﬁ-
cant impact on subsequent stroke rates. With nearly 200,000 strokes occurring in Italy 
each year, we wanted to examine how a shift in care pathways towards that outlined 
in phase 2 of the EXPRESS study could affect rates of stroke, and explore the ﬁnancial 
implications of such a shift in care pathway. METHODS: We developed an economic 
model to estimate the costs and savings associated with establishing a rapid assessment 
and treatment clinic for patients with suspected TIA in Italy, in line with phase 2 of 
the EXPRESS study. We used a population of 1,000,000 people with an assumed 
annual incidence of TIA of 0.058%. Current management was based on ESO guide-
lines and common clinical practice. We included direct costs associated with care 
(medications, diagnostics and staff—where data were unavailable, UK converted costs 
were used), and modelled the impact of changing management over three years. 
RESULTS: For a population of 1,000,000, changing the pathway of care to ensure 
rapid assessment and treatment for TIA patients would result in 180 future stroke 
events being avoided over three years. As a result, additional costs associated with 
changing the TIA pathway of care were offset by savings generated through avoiding 
acute stroke management costs. CONCLUSIONS: Our model suggests that imple-
menting a revised TIA care pathway in Italy would be cost saving. For a local popula-
tion of 1,000,000, savings associated with the avoidance of acute stroke management 
would offset the costs of establishing rapid assessment and treatment clinics for 
patients experiencing TIA.
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RECONFIGURING TIA CARE PATHWAYS IN HUNGARY: AVOIDING 
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OBJECTIVES: Due to lack of awareness of Transient Ischaemic Attack (TIA) symp-
toms, many patients may not immediately seek medical help, creating a delay in access 
to treatment. The UK EXPRESS study by Rothwell et al. (Lancet 2007;370:1432–42) 
demonstrated that greater focus on rapid assessment and management of TIA could 
signiﬁcantly reduce subsequent stroke rates. With over 42,000 hospitalisations due to 
strokes in Hungary each year, we wanted to examine how a shift in care pathways 
towards that outlined in the EXPRESS study could affect stroke rates, and explore 
the ﬁnancial implications of such a shift in care pathway. METHODS: We developed 
an economic model to estimate the costs and savings associated with establishing a 
rapid assessment and treatment clinic for patients with suspected TIA in Hungary, in 
line with phase 2 of the EXPRESS study. We used a population of 1,000,000 with an 
assumed annual TIA incidence of 0.042%. Current management was based on ESO 
guidelines and common clinical practice. We included direct costs associated with 
secondary care (medications, diagnostics and staff—where data were unavailable, 
converted UK costs were used), and modelled the impact of changing management 
over a three-year time horizon. RESULTS: For a population of 1,000,000, changing 
